



JIM GIBBONS
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **June 26, 2008** beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce
6671 Las Vegas Blvd. S., Suite 300
Las Vegas, NV**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 3 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of March 27, 2008, Meeting Minutes
- III. Old Business – Nebivolol (Bystolic®)
 - A. Public Comment
 - B. Presentation of Clinical Data by First Health Services
 - C. *Committee Discussion and Decision to Maintain Nebivolol on the PDL

ANNUAL REVIEW- DRUG CLASSES WITH PROPOSED CHANGES

- IV. Antidepressants: Other
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- V. Antihistamines: 2nd Generation
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

- VI. Cardiovascular: Antihyperlipidemics: Statins and Statin Combinations
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- VII. Cardiovascular: Antihyperlipidemics: Other
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- VIII. Ophthalmic Glaucoma Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- IX. Ophthalmic Quinolones
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- X. Respiratory: Long Acting Beta Adrenergic Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL
- XI. Respiratory: Nasal Corticosteroids
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion on the PDL

XII. Annual Review - Drug Classes without Proposed Changes

A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes

1. Analgesics: Long Acting Narcotics
2. Antibiotics: Cephalosporins 2nd Generation
3. Antibiotics: Cephalosporins 3rd Generation
4. Antibiotics: Macrolides
5. Antibiotics: Quinolones 2nd Generation
6. Antibiotics: Quinolones 3rd Generation
7. Anticoagulants: Injectable
8. Antidepressants: SSRIs
9. Antiemetics: Oral, 5-T3s
10. Antifungals: Onychomycosis Agents
11. Anti-Migraine Agents: Triptans
12. Bone Ossification Agents: Bisphosphonates
13. Cardiovascular: ACE Inhibitors & Diuretic Combinations
14. Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
15. Cardiovascular: Beta Blockers
16. Cardiovascular: Calcium Channel Blockers & Combinations
17. Central Nervous System: ADHD/Stimulants
18. Central Nervous System: Sedative Hypnotics
19. Electrolyte Depleters
20. Erythropoiesis Stimulating Proteins
21. Gastrointestinal Agents: H2RAs
22. Gastrointestinal Agents: PPIs
23. Growth Hormone Agents
24. Hepatitis C Agents
25. Herpetic Antiviral Agents
26. Immunomodulators: Injectable
27. Immunomodulators: Topical
28. Leukotriene Modifiers
29. Multiple Sclerosis Agents
30. Nasal Calcitonins
31. Ophthalmic Antihistamines
32. Otic Fluoroquinolones
33. Respiratory: Inhaled Anticholinergic Agents
34. Respiratory: Inhaled Corticosteroids/Nebs
35. Respiratory: Short Acting Beta Adrenergic-Inhalers/Nebs
36. Urinary Tract Antispasmodics

B. * Committee Discussion and Approval of Drug Classes without changes for the PDL

XIII. Report by FHSC on Brand Name Preferred Drugs Converted to Generic Status and the extension of existing product lines.

XIV. Review of Next Meeting Location, Date, and Time

XV. Public Comment

XVI. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.